NMRA Neumora Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why NMRA matters now
Neumora Therapeutics, Inc. Common Stock (NMRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.68 with +1.82% on the session and $311.3M in market capitalization; recent performance reads 1-month -9.58% and YTD -15.64%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-53.5M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -69.1%.
The latest indexable market news headline is "NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Ho Maykin filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.84
P/S
0.00
EV/EBITDA
-0.61
DCF Value
$1.10
FCF Yield
-69.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-181.7%
ROA
-144.5%
ROIC
-179.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-53.5M | $-0.30 |
| Q4 2025 | $0.00 | $-59.5M | $-0.35 |
| FY 2025 | $0.00 | $-236.9M | $-1.45 |
| Q3 2025 | $0.00 | $-56.8M | $-0.35 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$4.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.76
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.